Innoviva (INVA) EPS (Weighted Average and Diluted) Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -25,782.97% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 41.33% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.33% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.99% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.47% |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 74.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.19% |
| Sep 30, 2025 | -27.21% |
| Jun 30, 2025 | 148.79% |
| Mar 31, 2025 | -78.63% |
| Sep 30, 2024 | -71.89% |
| Jun 30, 2024 | -37.70% |
| Mar 31, 2024 | -18.19% |
| Sep 30, 2023 | 55.63% |
| Jun 30, 2023 | -69.28% |
| Mar 31, 2023 | -10.71% |
| Sep 30, 2022 | 98.13% |
| Jun 30, 2022 | -47.22% |
| Mar 31, 2022 | -13.59% |
| Sep 30, 2021 | 27.92% |
| Jun 30, 2021 | 22.47% |
| Mar 31, 2021 | 45.98% |
| Dec 31, 2020 | -0.67% |
| Sep 30, 2020 | 7.38% |
| Jun 30, 2020 | 32.00% |
| Mar 31, 2020 | 57.85% |
| Dec 31, 2019 | 24.05% |
| Sep 30, 2019 | 40.43% |
| Jun 30, 2019 | 37.78% |
| Mar 31, 2019 | 97.89% |
| Dec 31, 2018 | 288.20% |
| Sep 30, 2018 | 133.62% |
| Sep 30, 2016 | 31.91% |
| Jun 30, 2016 | 32.98% |
| Mar 31, 2016 | 28.11% |
| Sep 30, 2015 | 52.36% |
| Sep 30, 2013 | -13.58% |
| Jun 30, 2013 | -9.23% |